JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265491

Human UBE2J1 (UBC6e) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

UBE2J1 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 8 bp deletion in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

CGI-76, HSPC153, HSPC205, HSU93243, HSUBC6e, MGC12555, NCUBE-1, Non-canonical ubiquitin-conjugating enzyme 1, UB2J1_HUMAN, UBC6, UBC6E, Ubc6p, Ube2j1, Ubiquitin conjugating enzyme E2, J1 (UBC6 homolog, yeast), Ubiquitin conjugating enzyme E2, J1, U, Ubiquitin-conjugating enzyme E2 J1, Yeast ubiquitin-conjugating enzyme UBC6 homolog E

2 Images
Sanger Sequencing - Human UBE2J1 (UBC6e) knockout HeLa cell line (AB265491)
  • Sanger seq

Lab

Sanger Sequencing - Human UBE2J1 (UBC6e) knockout HeLa cell line (AB265491)

Sequencing chromatogram displaying sequence edit in exon 2

Sanger Sequencing - Human UBE2J1 (UBC6e) knockout HeLa cell line (AB265491)
  • Sanger seq

Unknown

Sanger Sequencing - Human UBE2J1 (UBC6e) knockout HeLa cell line (AB265491)

Homozygous : 8 bp deletion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 8 bp deletion in exon 2

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265491-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265491 Human UBE2J1 (UBC6e) knockout HeLa cell line", "number":"AB265491-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265491-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265491-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265491-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265491 Human UBE2J1 (UBC6e) knockout HeLa cell line", "number":"AB265491-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265491-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265491 Human UBE2J1 (UBC6e) knockout HeLa cell line", "number":"AB265491-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265491-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265491 Human UBE2J1 (UBC6e) knockout HeLa cell line", "number":"AB265491-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
UBE2J1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

UBC6e also known as UBE2J2 is a ubiquitin-conjugating enzyme with a molecular mass of approximately 33 kDa. It resides within the membrane of the endoplasmic reticulum (ER) where it functions as an E2 enzyme. UBC6e facilitates the transfer of ubiquitin from E1 activating enzymes to substrate proteins signaling these proteins for degradation. This enzyme's role is essential for controlling protein quality preventing accumulation of misfolded proteins within the ER.
Biological function summary

UBC6e contributes significantly to the ER-associated degradation (ERAD) pathway. The protein operates as part of a larger complex that identifies and targets defective proteins for ubiquitination and subsequent breakdown. Its activity maintains cellular homeostasis by regulating the protein landscape in the ER. The presence of UBC6e ensures only properly folded proteins proceed to the Golgi apparatus reducing the potential for cellular malfunction due to protein misfolding.

Pathways

UBC6e plays a critical role in the unfolded protein response (UPR) and proteostasis networks. The UPR pathway involves proteins like IRE1 and ATF6 working with UBC6e to alleviate ER stress by degrading misfolded proteins. Another pathway related to UBC6e is the proteasome degradation pathway which relies on activities like those of UBC6e and other E2 enzymes to clear misfolded proteins. Together these pathways help the cell manage stress and adapt to environmental changes.

UBC6e has connections with neurodegenerative diseases and certain types of cancer. Its involvement in ERAD relates it to diseases like Alzheimer's where protein misfolding and aggregation are problematic. Furthermore alterations in UBC6e activity intersect with proteins like p53 linking it to cancer progression. Dysregulation of ubiquitination involving UBC6e may contribute to both disease states highlighting its potential as a target for therapeutic intervention.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com